Please assess the completion status of the following clinical trial:

Trial Title: Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA, as defined by fulfilling at least four of seven American College of Rheumatology (ACR) criteria~* Positive for rheumatoid factor (RF) and/or anticyclic citrullinated peptide (CCP)~* The presence of arthritis symptoms for more than 6 weeks but less than 1 year~* Active RA, as defined by at least four swollen joints, at least four tender joints, and either an erythrocyte sedimentation rate (ESR) of greater than 30 mm/hr OR C-reactive protein level greater than 1.0 mg/dL (normal less than 0.4)~* Willing to adhere to the study requirements~* Willing to use acceptable effective forms of contraception~Exclusion Criteria:~* Allergy to methotrexate (MTX)~* Previous exposure to anti-CD20 monoclonal antibody (mAb) or other type(s) of mAb therapy~* Previous disease-modifying anti-rheumatic drugs (DMARD) therapy~* Previous use of a biologic agent~* Currently taking daily oral steroid doses of greater than 7.5 milligrams (mg)~* Receipt of intra-articular injections within 4 weeks prior to study entry~* Current peptic ulcer disease (PUD)~* Unwilling to stop drinking alcohol (ETOH)~* History of alcohol or substance abuse~* Active infection, or chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., Human Immunodeficiency Virus \[HIV\], hepatitis B virus \[HBV\], hepatitis C virus \[HCV\], tuberculosis \[TB\])~* Interstitial lung disease observed by chest x-ray \[chest radiograph\]~* Known coronary artery disease or significant cardiac arrhythmias or severe congestive heart failure (New York Heart Association \[NYHA\] classes III or IV)~* Definitive diagnosis of another autoimmune rheumatologic disease (e.g., systemic lupus erythematosus \[SLE\], scleroderma, primary Sjögren's syndrome, primary vasculitis)~* History of immunoglobulin E (IgE)-mediated or non-IgE-mediated hypersensitivity or known anaphylaxis to mouse proteins~* History of cancer. Exception: participants with previous resected basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ Grade I cervical cancer within 5 years prior to study entry are not excluded from study eligibility~* History of positive purified protein derivative (PPD) test (i.e., positive tuberculosis \[TB\] test) without treatment for TB infection or chemoprophylaxis for TB exposure~* History of inflamed pancreas~* Live vaccine within 3 months of study entry~* Certain abnormal laboratory values~* Require certain medications~* Any psychiatric disorder that would prevent a participant from providing informed consent~* Any condition or treatment (including biologic therapies) that, in the opinion of the investigator, may place the participant at unacceptable risk during the study~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues